Related Experiment Videos

PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway

Naoto Yoshizuka1, Maoyi Lai, Rong Liao

  • 1Department of Molecular Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd, La Jolla, CA 92037, USA.

Molecular Cancer Research : MCR
|June 6, 2012
PubMed

Insights

Protein kinase PRAK suppresses hematopoietic cancer by inhibiting the c-jun-NH(2)-kinase (JNK) pathway. PRAK deletion accelerates cancer, indicating its role as a tumor suppressor.

Area of Science:

  • Molecular Biology
  • Oncology
  • Signal Transduction

Background:

  • The p38 MAPK pathway is crucial in regulating cellular processes, including cancer.
  • Protein kinase PRAK, a p38 substrate, has been linked to suppressing skin cancer.
  • The role of PRAK in hematopoietic malignancies is not well understood.

Purpose of the Study:

  • To investigate the role of PRAK in hematopoietic cancer development.
  • To elucidate the molecular mechanisms underlying PRAK's function in tumorigenesis.
  • To determine if PRAK acts as a tumor suppressor in hematopoietic cancers.

Main Methods:

  • Utilized a mouse model with oncogenic N-Ras(G12D) expression in hematopoietic cells.
  • Assessed hematopoietic cancer development following PRAK deletion.
  • Analyzed the activation status of the JNK pathway in vivo and in primary cells.
  • Evaluated cell proliferation, colony formation, and senescence markers.

Main Results:

  • PRAK deletion accelerated hematopoietic cancer development in the Emicro-N-Ras(G12D) mouse model.
  • PRAK deficiency led to hyperactivation of the JNK pathway in hematopoietic cells.
  • PRAK deficiency enhanced oncogenic ras-induced proliferation and colony formation in a JNK-dependent manner.
  • Deletion of PRAK abrogated ras-induced senescence marker accumulation.

Conclusions:

  • PRAK functions as a tumor suppressor in hematopoietic cancer by antagonizing oncogenic ras-induced JNK pathway activation.
  • PRAK deficiency promotes hematopoietic tumorigenesis through JNK pathway hyperactivation.
  • These findings suggest PRAK may have a broader role as a tumor suppressor in various cancers.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...